Leukemia, Myeloid, Acute
Conditions
Keywords
AC220, Acute Myeloid Leukemia (AML), Transplantation, Stem Cell Transplantation, Allogeneic Transplantation, FMS-like tyrosine kinase (FLT3), FMS-like tyrosine kinase (FLT3) Inhibitor, Kinase, Kinase Inhibitor, Pharmacokinetics, ASP2689, quizartinib
Brief summary
The purpose of this study is to define a safe dose of AC220 when given as maintenance therapy after treatment with an allogeneic stem cell transplant.
Detailed description
This is a two-part, sequential group dose escalation study. In Part 1, subjects will be enrolled into successive cohorts to determine the maximum tolerated dose (MTD). Dose escalation decision will be made based on dose limiting toxicities (DLTs) that occur in subjects treated to date at a given dose level. In Part 2, a confirmation cohort will be opened to confirm the safety at the MTD. Subjects who have had an allogeneic Hematopoietic Stem Cell Transplant (HSCT) will enter treatment with AC220 between 30 to 60 days after receiving allogeneic HSCT. AC220 will be administered every day, with 28 consecutive days defined as a treatment cycle. Subjects may receive up to 24 continuous treatment cycles. Subjects will have study visits each week for the first 2 cycles, and then on Day 1 of each cycle after that.
Interventions
DRUGAC220
Oral Liquid
Sponsors
Ambit Biosciences Corporation
Daiichi Sankyo
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject has a diagnosis of acute myeloid leukemia (AML) according to WHO classification (2008) and has received a high dose or a reduced intensity conditioning allogeneic Hematopoietic Stem Cell Transplant (HSCT) during first or second remission and within 30 to 60 days prior to first dose of AC220. Donors may be human leukocyte antigen (HLA)-matched for HLA-A, B, C, DRB1, and DQB1 by high resolution typing, related or unrelated (only a single allele disparity will be allowed for HLA-A, B, or C as defined by high resolution typing) Note: more than one HSCT is allowed * Subject must be in morphologic remission (\< 5% marrow blasts) and without active central nervous system (CNS) AML within 14 days prior to first dose of AC220 * Subject must have CD3 donor chimerism \> 50 % at Screening * Subject has a Karnofsky Performance Status (KPS) of ≥ 60 * Subject must have absolute neutrophil count (ANC) \> 1000/mm3 and platelet count \> 50,000/mm3 without platelet transfusion support within 2 weeks prior to first dose * Subject must have adequate renal, hepatic, and coagulation parameters * Female subjects must not be lactating and must not be breastfeeding at Screening or during the study period and for 28 days \[or five half lives of the study drug whichever is longer\] after final study drug administration. * Subject is able to comply with study procedures and follow-up examinations
Exclusion criteria
* Subject received AC220 and relapsed during treatment with AC220 * Subject has active ≥ Grade 2 graft versus host disease (GVHD) * Subject has received concurrent chemotherapy, immunotherapy, or radio-therapy within 21 days prior to the first dose of AC220, or any antineoplastic therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation) within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug * Subject requires treatment with concomitant drugs that prolong QT/QTc interval or strong cytochrome P-3A4 (CYP3A4) inhibitors or inducers with the exception of immunosuppressants, antibiotics, antifungals, and antivirals that are used as standard of care post-transplant or to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the subject * Subject requires treatment with anticoagulant therapy * Subject has a known positive test for human immunodeficiency virus, hepatitis C, or hepatitis B surface antigen * Subject had major surgery within 4 weeks prior to first dose of AC220 * Subject has uncontrolled or significant cardiovascular disease * Subject has an active acute fungal, bacterial, or other infection that is unresponsive to therapy * Subject has participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half lives whichever is longer, prior to the initiation of Screening. * Subject has any medical, psychiatric, addictive or other kind of disorder which compromises the ability of the subject to give written informed consent and/or to comply with procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of dose limiting toxicity (DLT) | up to Day 56 | From first dose through last dose of Cycle 2 |
| Safety assessed by recording adverse events, physical examinations, vital signs, electrocardiograms (ECGs) and laboratory assessments | 30 days after last subject discontinues treatment (maximum of 24 months) | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival | 30 days after last subject discontinues treatment (maximum of 24 months) | Time from first dose until date of relapse or death |
| Overall survival | 30 days after last subject discontinues treatment (maximum of 24 months) | Time from first dose until date of death from any cause |
| Percentage of transplant rejections | 30 days after last subject discontinues treatment (maximum of 24 months) | Through End of Treatment |
| Duration of confirmed complete remission (CR) | 24 months | Time from first dose until date of relapse |
| Percentage of Donor Chimerism | Up through 24 months of treatment | — |
| Treatment-related mortality (TRM) | Up through 24 months of treatment | Death in CR (CR, CRm, CRp and CRi) |
| Composite of pharmacokinetics: AUC24 , Cmax, Ctrough and Tmax | Up through 24 months of treatment | — |
| Percentage of Subjects with Graft-versus-Host Disease (GVHD) | Up through 24 months of treatment | — |
| Duration of overall complete remission | 24 months | Complete remission (CR) + CR with incomplete platelet recovery (CRp) + CR with incomplete hematologic recovery (CRi) + complete molecular remission (CRm) |
Countries
United States
Outcome results
None listed